The Europeans also get the corona vaccine from the US manufacturer Moderna, which is considered very promising.
The EU Commission has negotiated a framework agreement for up to 160 million cans, as announced by Commission head Ursula von der Leyen. The contract is to be formally sealed on Wednesday.
The EU Commission now has contracts with the manufacturers of all three vaccines, which are given the best chance of rapid approval in the coming weeks. In addition to Moderna, these are Biontech / Pfizer and Astrazeneca. All three had announced promising test data in the past few days. Accordingly, all three vaccines are effective and well tolerated.
No corona vaccine has yet been approved in Europe. The Federal Government and the EU Commission expect the first licenses to be issued in December. Before this, however, an examination by the European Medicines Agency (EMA) is necessary.
The moderna vaccine that has now been ordered has an effectiveness of 94.5 percent according to the manufacturer. The EMA has started what is known as a rolling review process for the preparation, which aims to obtain approval relatively quickly.
The EU Commission concludes framework agreements with manufacturers on behalf of the 27 member states. On the one hand, these contracts contain advance payments so that the pharmaceutical companies can set up production quickly, and on the other hand, rights of first refusal for the EU states. Once a product has been approved, all 27 states are to have access to it at the same time, although initially only in small quantities depending on production capacity.
They are distributed in the EU according to the size of the population. Germany has a share of 18.6 percent. In Germany, on the other hand, risk groups and health workers are likely to be vaccinated first. It will be months before everyone has the chance of a protective spade.
Brussels secured a wide range of vaccines while they were being developed, also in the expectation that not all of them would work smoothly. However, if the hopes for the promising vaccines are fulfilled, the EU will ultimately have more than enough units for all around 450 million inhabitants, even if the vaccines usually have to be given twice.
In addition to the 160 million cans from Moderna, the EU Commission has secured up to 300 million cans from Biontech / Pfizer and a further 300 million cans from Astrazeneca. There are also other contracts with manufacturers that are not quite that far in development: up to 405 million cans from the German manufacturer Curevac, up to 300 million cans from Sanofi-GSK and up to 200 million cans from Johnson & Johnson.
© dpa-infocom, dpa: 201124-99-445228 / 4 (dpa)